2024 Annual Conference

The Consortium on Substance Use and Addiction (CSUA) invites you to join us on

Monday, April 29th for our annual conference!

Please note that the conference is free for all attendees, but registration is required. We encourage people to join us in-person at the Barron Innovation Hub at the University Campus with an optional Zoom stream for both the morning and afternoon sessions. Please contact Paul Griffin, CSUA Interim Director, with any questions.

This year’s keynote speaker will be R. Lorraine Collins, Distinguished Professor, Director of the Center for Cannabis and Cannabinoid Research from the University at Buffalo. The full day agenda is available below.

Register Now

​

Since 2008, Dr. Collins has served as Associate Dean for Research and Professor of Community Health and Health Behavior in the School of Public Health and Health Professions at the University at Buffalo (UB). In 2022 she was designated a SUNY Distinguished Professor. In 2021, she was designated the Director of UB’s Center for Cannabis and Cannabinoid Research (CeCaR@buffalo.edu)

Specific to cannabis research and policy, in June 2016, Dr. Collins was appointed to a National Academies of Sciences, Engineering and Medicine’s ad hoc committee that reviewed the health effects of cannabis. In that role, she reviewed research on psychosocial aspects of cannabis use and contributed to a comprehensive document that described the current state of evidence on the health effects of cannabis and made policy recommendations for research (NAS, 2017). That review continues to provide useful information to a range of audiences, including researchers and medical personnel, persons who consume cannabis, and some marketers of cannabis products.

In 2018, Dr. Collins was appointed by the then New York Governor, Andrew Cuomo, to serve as a member of a workgroup to draft legislation for a regulated adult-use cannabis program in New York State. That work served as the basis for New York’s recreational cannabis law, which was passed by the Legislature and signed by Governor Hochul in March 2021. In 2023, cannabis became available at retail outlets in New York State.

Dr. Collins has a well-established publication record in addictions research and a decades long history of NIH-funded research as a Principal Investigator (PI) and Co-Investigator (Co-I). Among other federally-funded grants, she developed and pilot-tested a smartphone application to reduce cannabis use and promote exercise among young adults; introduced behavioral economics principles and experimental methods to research on cannabis use; and was among the first to examine the concurrent and separate use of alcohol (malt liquor) and cannabis among emerging and young adults.

Dr. Collins received my BA in Psychology from McGill University (Montreal, Canada) and her MS and PhD degrees in Psychology (Clinical) from Rutgers University (New Brunswick, NJ). She completed her clinical internship and postdoctoral training at the University of Washington (Seattle, WA). Her research interests are focused on substance use and misuse, including: 1) cognitive and behavioral approaches to the conceptualization, prevention, and treatment of addictive behaviors; 2) the role of policy in cannabis/substance use; and 3) the role of psycho-social factors (e.g., gender, ethnicity) and mental health issues. During the past two decades, she has contributed to expanding the methods for collecting prospective ecological momentary assessment (EMA) data, in real-time.

• How do Social Determinants of Health Impact Smoking Cessation for African Americans? A Scoping Review
  • Abena A. Duah, Victoria Nicole Francois, Subekshya Upadhyay, Sophia I. Allen
• The Unintended Adverse Health Consequences of Drug-Induced Homicide Laws: Evidence from Pennsylvania
  • Kim Gannon, Gregg Gonsalves, Mark Schlesinger, Susan Busch
• Judge Demographics and Their Impact on Sentencing of Drug Crimes: Using PA Commission of Sentencing Data to Examine Drug Sentencing Severity
  • Sarah Henry Davis, Abenna Jones, Megan Kurlychek
• The Neural Substrates of Inhibitory Control in Abstinent Smokers – A Functional Magnetic Resonance Imaging Study
  • Kalin Z. Salinas, Kenneth R. Houser, Candace R. Bordner, Alan Fendrich, Jonathan Foulds, Alfredo Bellon, Qing X. Yang, Joshua E. Muscat, Stephen J. Wilson, Jason Liao, Andrea L. Hobkirk
• Broadband Access, Local MOUD Treatment, and Opioid Overdose Deaths Post-Covid
  • Zhen Lei, Mengjun Ge, Kristina Brant
• The Impact of Prenatal and Postnatal Substance Use on Late Adolescent Substance Use via Early Adolescent Processes
  • R. C. Marcus and R. D. Eiden
• Adolescent Nicotine Alters Adult Prelimbic Cortical Dendritic but not Cingulate Dendritic Morphology
  • Anna Tischer, Thomas J. Gould, Carlos Novoa
• The Effectiveness of Recovery Support Services: A Longitudinal Analysis
  • Erik Dolgoff
• The Role of Perceived, Enacted, and Internalized Stigma on the Uptake of Medications for Opioid Use Disorder (MOUD) Among Women in the Criminal Legal System
  • O. H. Quadri, E. M. Skogseth, K. Brant, E. Harrison, A. A. Jones
• Ibogaine as a Novel Treatment for Opioid Use Disorder Susan Ousterman Accessibility Barriers to Medications for Opioid Use Disorder Treatment: A Qualitative Study of Perspectives from Women with Opioid Use Disorder and Health and Criminal Justice Professionals
  • E. Skogseth, K. Brant, C. Latkin, A. A. Jones AI in Substance Use Treatment Sam Ortbal
• Prenatal Tobacco Exposure: Pathways to Aggression and Social Competence in Kindergarten
  • Makenna M. Luzenski, Madison R. Kelm, Krisin J. Perry, Rina D. Eiden
• Challenges and Recommendations for Overdose Prevention and Harm Reduction in an Era of Fentanyl and Xylazine: Perspectives of Women with Opioid Use Disorder and Professionals
  • Harrison, E.D., Brant, K, Strong-Jones, S, Skogseth, E, Latkin, C, Jones, A.A.
• Cannabis Policy Bundles and Traffic Fatalities in the American States Over Time
  • Mingean Park, Daniel J. Mallinson, Shazib Altaf, Lilliard E. Richardson Jr.
• Evaluating the Validity and Correlation of Existing E-Cig Dependence Measures among Exclusive E-cig Users
  • Rhea Kanwar, Jacob R. Miller, Jonathan Foulds, Gail D’Souza, Jessica Yingst